GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Guided Therapeutics Inc (OTCPK:GTHP) » Definitions » Equity-to-Asset

Guided Therapeutics (Guided Therapeutics) Equity-to-Asset : -2.28 (As of Dec. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Guided Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Guided Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-3.81 Mil. Guided Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $1.67 Mil. Therefore, Guided Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was -2.28.

The historical rank and industry rank for Guided Therapeutics's Equity-to-Asset or its related term are showing as below:

GTHP' s Equity-to-Asset Range Over the Past 10 Years
Min: -67.05   Med: -4.44   Max: -0.86
Current: -2.28

During the past 13 years, the highest Equity to Asset Ratio of Guided Therapeutics was -0.86. The lowest was -67.05. And the median was -4.44.

GTHP's Equity-to-Asset is ranked worse than
97.13% of 871 companies
in the Medical Devices & Instruments industry
Industry Median: 0.65 vs GTHP: -2.28

Guided Therapeutics Equity-to-Asset Historical Data

The historical data trend for Guided Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guided Therapeutics Equity-to-Asset Chart

Guided Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14.35 -8.04 -2.67 -0.86 -2.28

Guided Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.86 -0.99 -1.41 -1.95 -2.28

Competitive Comparison of Guided Therapeutics's Equity-to-Asset

For the Medical Devices subindustry, Guided Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guided Therapeutics's Equity-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Guided Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Guided Therapeutics's Equity-to-Asset falls into.



Guided Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Guided Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-3.806/1.669
=-2.28

Guided Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-3.806/1.669
=-2.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Guided Therapeutics  (OTCPK:GTHP) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Guided Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Guided Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Guided Therapeutics (Guided Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
5835 Peachtree Corners East, Suite B, Norcross, GA, USA, 30092
Guided Therapeutics Inc is a medical technology company. It is engaged in developing medical devices that have the potential to improve healthcare. Its primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device and extension of its cancer detection technology into other cancers, including esophageal. The company generates revenue from the sale of medical devices.
Executives
John E Imhoff director, 10 percent owner P.O. BOX 31083, SEA ISLAND GA 31561
Alan Grujic director 349 FORBES AVE, SAN RAFAEL CA 94901
Michael C James director 2040 MAIN STREET, SUITE 225, IRVINE CA 92614
Richard P. Blumberg director 2357 HOBART AVENUE S.W., SEATTLE WA 98116
Lynne H Imhoff 10 percent owner 2716 SOUTH ROCKFORD ROAD, TULSA OK 74114
Gene S Cartwright officer: Chief Executive Officer 4088 COMMERCIAL AVE, NORTHBROOK IL 60062
Parsons & Whittemore Enterprises Corp. 10 percent owner 4 INTERNATIONAL DRIVE, RYE BROOK NY 10573
George F. Landegger 2010 10-year Grat 10 percent owner 4 INTERNATIONAL DRIVE, RYE BROOK NY 10573
George F Landegger 10 percent owner 4 INTERNATIONAL DRIVE, RYE BROOK, NEW YORK NY 10573
Whittemore Collection Ltd 10 percent owner 4 INTERNATIONAL DRIVE, RYE BROOK NY 10573
George F. Landegger 2010 5-year Grat 10 percent owner 4 INTERNATIONAL DRIVE, RYE BROOK NY 10573
Linda Rosenstock director 5995 PLAZA DRIVE, MAIL STOP CY20-103, CYPRESS CA 90630
Jonathan M Niloff director C/O MATRITECH, INC., 330 NEVADA STREET, NEWTON MA 02460
Ronald W Allen director P O BOX 1734, ATLANTA GA 30301
Shabbir Bakir Bambot officer: VP of R & D 4955 AVALON RIDGE PARKWAY, SUITE 300, NORCROSS GA 30071

Guided Therapeutics (Guided Therapeutics) Headlines